Please login to the form below

Not currently logged in
Email:
Password:

cinacalcet

This page shows the latest cinacalcet news and features for those working in and with pharma, biotech and healthcare.

NICE set to back Parsabiv for kidney disease complication

NICE set to back Parsabiv for kidney disease complication

be treated with Amgen's older drug Sensipar/Mimpara (cinacalcet) - and provided Amgen supplies the drug at an agreed discount. ... Specifically, it is administered three times a week as an infusion at the end of the dialysis process, while cinacalcet

Latest news

  • Amgen's chronic kidney disease drug Parsabiv cleared in US Amgen's chronic kidney disease drug Parsabiv cleared in US

    Parsabiv (etelcalcetide) - a follow-up to Amgen's blockbuster Sensipar/Mimpara (cinacalcet) - has been given a green light to treat adult CKD patients on dialysis who develop secondary hyperparathyroidism (sHPT).

  • FDA knocks back Amgen's chronic kidney disease treatment FDA knocks back Amgen's chronic kidney disease treatment

    The rejection is a big disappointment for Amgen, which had suggested that Parsabiv (also known as velcalcetide and AMG 416) could equal and potentially exceed Sensipar (cinacalcet) as a revenue driver.

  • Amgen's Sensipar follow-up clears phase III trial Amgen's Sensipar follow-up clears phase III trial

    Now, Amgen is edging close to bringing a successor to Sensipar (cinacalcet) to market after follow-up AMG 416 (formerly known as velcalcetide) met its objectives in a phase III trial

  • Amgen profits down on rising costs Amgen profits down on rising costs

    Among Amgen's other new products, Sensipar/Mimpara (cinacalcet) for hyperparathyroidism grew 19 per cent to $256m, while Xgeva and Prolia (both denosumab) for preventing bone fractures rose 72 per cent

  • Amgen buoyant as profits rise in Q3 Amgen buoyant as profits rise in Q3

    Hyperparathyroidism drug Sensipar/Mimpara (cinacalcet) had a good quarter, up 18 per cent to $243m, while colorectal cancer drug Vectibix (panitumumab) rose 11 per cent to $88m.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics